FeesSafety
Pluang+

Blue Ridge Bankshares reports Q3 2026 net loss amid credit provisions and merger costs, but shows improved loan growth and margins.

Company Fundamentals
27 Oct 2026, 00:00 WIB
PRNewsWire
View Source
Bearish
Blue Ridge Bankshares reports Q3 2026 net loss amid credit provisions and merger costs, but shows improved loan growth and margins.

Blue Ridge Bankshares posted a net loss of $4.2 million in Q3 2026, driven by $6.6 million in credit loss provisions related to legacy loans and $0.9 million in merger expenses. Despite the loss, the bank improved its net interest margin to 3.08% and grew loans held for investment by $33.1 million. The company is progressing with a planned merger with HomeTrust Bancshares, expected to close in early 2027. Operational improvements in loan yields, deposit mix, and expense control suggest a focus on strengthening profitability ahead of the merger.

Blue Ridge Bankshares' Q3 2026 results provide context for readers following financial sector developments. As of Oct 27, 2026 03:21 WIB, among 142 priced Financials-sector US stocks tradable on Pluang, 76 rose and 66 fell. Notable movers include WULF at USD 11.93 with a 1-day change of +5.39% and Pluang order activity of 81% Sell / 19% Buy, GEMI at USD 2.90 down -5.23% with 6% Sell / 94% Buy activity, and CG at USD 39.19 up +5.15% with a typical hold time of 113 days.

More News

Exodus Movement to announce Q3 2026 financial results on Nov 9 with a webcast.

Exodus Movement to announce Q3 2026 financial results on Nov 9 with a webcast.

Exodus Movement, a self-custodial finance and payments platform, will release its third quarter 2026 financial results after market close on November 9, 2026. The company will host a webcast at 5:00 PM ET the same day to discuss the results. Founded ...

Company Fundamentals
Neutral
1 hour ago
Onco360 named national pharmacy partner for AstraZeneca's lung cancer drug Zegfrovy.

Onco360 named national pharmacy partner for AstraZeneca's lung cancer drug Zegfrovy.

Onco360, a leading independent specialty pharmacy, has been selected by AstraZeneca as a national pharmacy partner for Zegfrovy (sunvozertinib), a treatment for advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. Zegfrovy has s...

Market News
Bullish
1 hour ago
S4A IT Solutions joins SAP PartnerEdge program, boosting its SAP consulting capabilities.

S4A IT Solutions joins SAP PartnerEdge program, boosting its SAP consulting capabilities.

S4A IT Solutions has been accepted into the SAP PartnerEdge program, marking a key milestone in its growth. This partnership enhances S4A's ability to help organizations maximize their SAP investments, especially in areas like asset management and su...

Market News
Bullish
1 hour ago
SEC policy shifts and rising shareholder activism shape 2027 proxy season preparations for public companies

SEC policy shifts and rising shareholder activism shape 2027 proxy season preparations for public companies

Public companies are facing new challenges for the 2027 proxy season due to changes in SEC policies, evolving shareholder activism strategies, and shifts in institutional investor voting. A virtual roundtable on October 28 will gather experts to disc...

Market News
Neutral
3 hours ago
Gogo to release Q3 2026 earnings on Nov 6 with a conference call for analysts.

Gogo to release Q3 2026 earnings on Nov 6 with a conference call for analysts.

Gogo Inc., a leading provider of in-flight broadband connectivity, announced it will report its third quarter 2026 financial results on November 6, 2026, before the market opens. The company will hold a conference call with financial analysts the sam...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App